ClinicalTrials.gg

Anemia, Sickle Cell clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,136 studies for Anemia, Sickle Cell across more than 10 countries. 240 are recruiting or about to start. 889 of them are mainly about Anemia, Sickle Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 4 narrower conditions too, such as Vaso-Occlusive Crises: 1,178 studies, 245 open.

ClinicalTrials.gov finds 1,214 studies for Anemia, Sickle Cell. How that becomes 1,136 here

This page counts the studies the registry files under Anemia, Sickle Cell, and those it files under no condition that list Anemia, Sickle Cellthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 1,214Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −42Filed under a narrower condition, counted on its own pageSickle Cell Trait 15 · Vaso-Occlusive Crises 15 · Hemoglobin SC Disease 6 · Acute Chest Syndrome 5
  3. −5List Anemia, Sickle Cell as a condition, but the registry did not file them under itMost often written as “Sickle Cell Anemia in Children” (3) and “Healthy Volunteers Sickle Cell Disease, Thalassemia” (2). The registry filed them under other conditions only, most often Thalassemia (2) and Vitamin D Deficiency (1).
  4. −31Match it another way27 name it in the title and 4 by a synonym or other text the search reads.
  5. 1,136The count on this page12 of them list Anemia, Sickle Cell in their own words; the registry filed them under no condition.

Status

Completed
604
Recruiting
177
Terminated
125
Active, not recruiting
62
Status unknown
55
Not yet recruiting
50

Phase

Phase 2
297
Phase 1
184
Phase 3
110
Phase 4
38
Early Phase 1
15

Where

United States
733
France
132
United Kingdom
76
Canada
55
Italy
43
Nigeria
37

Who develops what

Add Anemia, Sickle Cell to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 11 programs from 8 companies, 10 with this as their studies’ main aim; 5 with a live phase 3 study; 6 primary completions in the next 12 months. Compare Agios Pharmaceuticals, CSL and Sanofi here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
HydroxyureaRecent, limited
Evidence
  • NCT05953584 · Novo Nordisk A/S · Phase 2 · live · background · “Hydroxyurea” · registered Jul 2023
Norgine33% of its industry studiesUS: off-patent, 5 generics marketedEU: Norgine (EMA 2007) + 1 other11 study
FamotidineRecent, limited
Evidence
  • NCT06481306 · Bristol-Myers Squibb · Phase 2 · live · background · “Famotidine” · registered Jun 2024
Leidos Life Sciences17% of its industry studiesUS: off-patent, 53 generics marketed11 study
PantoprazoleRecent, limited
Evidence
  • NCT06481306 · Bristol-Myers Squibb · Phase 2 · live · background · “Pantoprazole” · registered Jun 2024
Takeda22% of its industry studiesUS: off-patent, 27 generics marketedEU: Takeda (EMA 2009)11 study

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Pneumococcal 21-Valent Conjugate Vaccine☆ Track1 live phase-3 study: NCT07247188Sanofi
rilzabrutinibApproved: US 2025 · EU 2025☆ Track1 live phase-3 study: NCT06975865Sanofi
etavopivat☆ Track2 live phase-3 studies: NCT06612268, NCT04624659Novo Nordisk A/S
mitapivatApproved: US 2022 · EU 2022☆ Track2 live phase-3 studies: NCT07656415, NCT05031780Agios Pharmaceuticals, Inc.

The 4 in phase 3 with the nearest primary completion, of 11 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (6)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 7 Jan 2027 est.Pneumococcal 21-Valent Conjugate Vaccine · Sanofi · Phase 3 main aimvs Pneumococcal 20-Valent Conjugate VaccineNCT07247188 Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — primary endpoint: Number of participants reporting immediate adverse events (AEs) · 100 enrolled
  • Jun 2027 est.Citrulline · Asklepion Pharmaceuticals, LLC · Phase 3 named, not the main aimNCT06989567 A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis — primary endpoint: Change in pain score from baseline to discharge · 120 enrolled
  • 23 Jul 2027 est.rilzabrutinib · Sanofi · Phase 3 main aimNCT06975865 The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — primary endpoint: Annualized rate of clinical VOC · 192 enrolled

3 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Anemia, Sickle Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 10 open · Alkylating agents 5 open · Tyrosine kinase inhibitors (TKIs) 3 open · Opioids 2 open · Calcineurin inhibitors 2 open

Coming up

86studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger. 127 (72%) take children under 18. 6 (3%) are for women only and 0 (0%) for men only; 29 (16%) take healthy volunteers.

Recruiting studies that take each age, of 177
AgeWomenMen
1079 (45%)78 (44%)
18153 (86%)148 (84%)
30121 (68%)117 (66%)
40109 (62%)105 (59%)
50104 (59%)100 (56%)
6588 (50%)86 (49%)
7580 (45%)78 (44%)
8577 (44%)75 (42%)

Across all 1,136 studies, recruiting or not: 56% stop at 75 or younger and 54% at 65; 65% take children; 2% are for women only and 1% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Anemia, Sickle Cell studies take

Of 93 phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 46 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 136 mo18–65 · 58 studies24 mo9–41 · 28 studies—
Phase 1/282 mo44–222 · 37 studies——
Phase 246 mo24–73 · 93 studies28 mo16–41 · 34 studies54 mo42–117 · 59 studies
Phase 348 mo36–61 · 35 studies——
Phase 424 mo13–41 · 20 studies——
Interventional, no phase28 mo15–49 · 173 studies—28 mo17–54 · 165 studies
Observational49 mo24–109 · 139 studies—48 mo23–109 · 130 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,136. Browse all 1,136 → or search them.